Cargando…

Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients

BACKGROUND: The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short...

Descripción completa

Detalles Bibliográficos
Autores principales: Krohe, Meaghan, Tang, Derek H., Klooster, Brittany, Revicki, Dennis, Galipeau, Nina, Cella, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542025/
https://www.ncbi.nlm.nih.gov/pubmed/31142325
http://dx.doi.org/10.1186/s12955-019-1162-5
_version_ 1783422862960361472
author Krohe, Meaghan
Tang, Derek H.
Klooster, Brittany
Revicki, Dennis
Galipeau, Nina
Cella, David
author_facet Krohe, Meaghan
Tang, Derek H.
Klooster, Brittany
Revicki, Dennis
Galipeau, Nina
Cella, David
author_sort Krohe, Meaghan
collection PubMed
description BACKGROUND: The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 10b among patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. METHODS: Cognitive debriefing interviews sought to evaluate patients’ ability to read, understand, and meaningfully respond to the questionnaires, as well as to evaluate the questionnaires’ relevance in the target patient population. Interviews were conducted by telephone and lasted approximately 90 min. Audio recordings were transcribed, anonymized, and analyzed using qualitative data analysis software. RESULTS: Fifteen cognitive debriefing interviews were conducted with women (mean age 66.0 years [standard deviation = 12.4]). Patients reported metastases in the bone (86.7%), liver (20.0%), lung (13.3%), skin (6.7%), and lymph node (6.7%) (not mutually exclusive). All patients for whom data were available demonstrated understanding of the instructions and the recall period of the NFBSI-16 (n = 14/14, 100.0%) and the PROMIS (n = 14/14, 100.0%). Greater than 90% of patients demonstrated understanding of each of the items in the NFBSI-16 and the PROMIS. Greater than 70% of patients demonstrated understanding of the response options of the NFBSI-16, > 90% understood response options of PROMIS Items 1–6, and ≥ 50% understood response options of PROMIS Items 7–10. Conceptual relevance was supported for most items in both questionnaires based on patients’ reports of experiencing the concepts as part of their breast cancer experience. CONCLUSIONS: The results of the cognitive debriefing interviews provide evidence that the NFBSI-16 and PROMIS Physical Function Short Form 10b have content validity in the HR+/HER2- advanced breast cancer patient population. Patients may benefit from additional instructions at the point the response options reverse direction in the PROMIS.
format Online
Article
Text
id pubmed-6542025
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65420252019-06-03 Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients Krohe, Meaghan Tang, Derek H. Klooster, Brittany Revicki, Dennis Galipeau, Nina Cella, David Health Qual Life Outcomes Research BACKGROUND: The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form 10b among patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. METHODS: Cognitive debriefing interviews sought to evaluate patients’ ability to read, understand, and meaningfully respond to the questionnaires, as well as to evaluate the questionnaires’ relevance in the target patient population. Interviews were conducted by telephone and lasted approximately 90 min. Audio recordings were transcribed, anonymized, and analyzed using qualitative data analysis software. RESULTS: Fifteen cognitive debriefing interviews were conducted with women (mean age 66.0 years [standard deviation = 12.4]). Patients reported metastases in the bone (86.7%), liver (20.0%), lung (13.3%), skin (6.7%), and lymph node (6.7%) (not mutually exclusive). All patients for whom data were available demonstrated understanding of the instructions and the recall period of the NFBSI-16 (n = 14/14, 100.0%) and the PROMIS (n = 14/14, 100.0%). Greater than 90% of patients demonstrated understanding of each of the items in the NFBSI-16 and the PROMIS. Greater than 70% of patients demonstrated understanding of the response options of the NFBSI-16, > 90% understood response options of PROMIS Items 1–6, and ≥ 50% understood response options of PROMIS Items 7–10. Conceptual relevance was supported for most items in both questionnaires based on patients’ reports of experiencing the concepts as part of their breast cancer experience. CONCLUSIONS: The results of the cognitive debriefing interviews provide evidence that the NFBSI-16 and PROMIS Physical Function Short Form 10b have content validity in the HR+/HER2- advanced breast cancer patient population. Patients may benefit from additional instructions at the point the response options reverse direction in the PROMIS. BioMed Central 2019-05-29 /pmc/articles/PMC6542025/ /pubmed/31142325 http://dx.doi.org/10.1186/s12955-019-1162-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Krohe, Meaghan
Tang, Derek H.
Klooster, Brittany
Revicki, Dennis
Galipeau, Nina
Cella, David
Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
title Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
title_full Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
title_fullStr Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
title_full_unstemmed Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
title_short Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
title_sort content validity of the national comprehensive cancer network – functional assessment of cancer therapy – breast cancer symptom index (nfbsi-16) and patient-reported outcomes measurement information system (promis) physical function short form with advanced breast cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542025/
https://www.ncbi.nlm.nih.gov/pubmed/31142325
http://dx.doi.org/10.1186/s12955-019-1162-5
work_keys_str_mv AT krohemeaghan contentvalidityofthenationalcomprehensivecancernetworkfunctionalassessmentofcancertherapybreastcancersymptomindexnfbsi16andpatientreportedoutcomesmeasurementinformationsystempromisphysicalfunctionshortformwithadvancedbreastcancerpatients
AT tangderekh contentvalidityofthenationalcomprehensivecancernetworkfunctionalassessmentofcancertherapybreastcancersymptomindexnfbsi16andpatientreportedoutcomesmeasurementinformationsystempromisphysicalfunctionshortformwithadvancedbreastcancerpatients
AT kloosterbrittany contentvalidityofthenationalcomprehensivecancernetworkfunctionalassessmentofcancertherapybreastcancersymptomindexnfbsi16andpatientreportedoutcomesmeasurementinformationsystempromisphysicalfunctionshortformwithadvancedbreastcancerpatients
AT revickidennis contentvalidityofthenationalcomprehensivecancernetworkfunctionalassessmentofcancertherapybreastcancersymptomindexnfbsi16andpatientreportedoutcomesmeasurementinformationsystempromisphysicalfunctionshortformwithadvancedbreastcancerpatients
AT galipeaunina contentvalidityofthenationalcomprehensivecancernetworkfunctionalassessmentofcancertherapybreastcancersymptomindexnfbsi16andpatientreportedoutcomesmeasurementinformationsystempromisphysicalfunctionshortformwithadvancedbreastcancerpatients
AT celladavid contentvalidityofthenationalcomprehensivecancernetworkfunctionalassessmentofcancertherapybreastcancersymptomindexnfbsi16andpatientreportedoutcomesmeasurementinformationsystempromisphysicalfunctionshortformwithadvancedbreastcancerpatients